Fortis Malar (523696)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• ROE of 15.53% shows decent return on shareholders' equity.
• Piotroski F-Score of 6/9 suggests reasonable financial health on profitability, leverage, and efficiency metrics.
• Reported profit growth of 100% gives a low PEG of 0.22, though sustainability needs verification.
• Price is above the 52-week low of ₹40.75, indicating some market support.
• Small market cap of ₹123 Cr leaves room for operational improvements if executed well.

Concerns

• ROCE of just 0.83% means capital employed is generating negligible operating returns.
• Latest quarter sales and net profit are ₹0 Cr, making current business activity impossible to assess.
• Sales growth is 0.00%, with no dividend yield, so there is no evidence of compounding or shareholder payout.
• P/E of 22.32 for a no-growth, zero-dividend hospital with weak ROCE offers little margin of safety.

AI Analysis

As an investor, I like businesses that are simple, earn solid returns on tangible capital, and give me a margin of safety. Fortis Malar is a hospital, and I can understand that business. But the numbers here do not make me eager to pay ₹65.66. Book value is only ₹16.43, so the market is asking 4 times book. Return on equity is 15.53%, which is respectable, but return on capital employed is just 0.83%. That tells me equity returns may not be coming from a strong core franchise—or the capital base is too heavy relative to operating profits. Either way, it is not the kind of economics I look for. Sales growth is zero. Zero. The latest quarter shows ₹0 sales and ₹0 net profit. I cannot value a business on a blank quarter unless there is a clear, honest explanation. The reported 100% profit growth and PEG of 0.22 are tempting, but growth on stagnant revenue is usually arithmetic, not a durable moat. If revenue does not grow, profits cannot compound for long. There is no dividend, so the shareholder depends entirely on price change; that makes valuation discipline even more important. At 22.32 times earnings, I am being asked to pay up for no growth, nil dividend, negligible ROCE, and missing data on promoter holding. A Piotroski score of 6/9 is a mild positive, but it does not compensate for the lack of economic momentum. The 52-week range of ₹40.75 to ₹76.00 tells me the market itself has been uncertain. In my view this is closer to a slow grower or special situation, not a predictable compounding machine. Until I see real revenue, tangible returns on capital, and some indication of governance, I would keep this on the watchlist, not in the portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer